Debra Richardson, MD
Gynecologic Oncology · Oklahoma City, OKNPI 1992784987
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $81,370 of the $97,033 with a category attached, or 83.9%. 19 manufacturers reported payments, led by GSK at 37.7% of the total. Reporting peaked in 2024 at $33,546 and has fallen 79.9% since, to $6,741 in 2025. Among gynecologic oncology clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 98 payments — averaging $990.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$37K
- AstraZeneca$20K
- Genmab U.S., Inc.$11K
- Karyopharm Therapeutics Inc.$6K
- Foundation Medicine, Inc.$5K
- Eisai Inc.$5K
- plus $14K from 13 others
Across 918 payments — averaging $8588.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$3.6M
- AbbVie$1.3M
- Tesaro, Inc.$594K
- Aadi Bioscience, Inc.$582K
- Clovis Oncology, Inc.$316K
- Genmab U.S., Inc.$232K
- plus $1.3M from 16 others
What the payments were for
- Consulting fees$81,37084%
- Travel & lodging$11,41212%
- Food & beverage$4,1834%
- Education$680%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 15 | $36,578 |
| AstraZeneca | 20 | $19,757 |
| Genmab U.S., Inc. | 9 | $11,302 |
| Karyopharm Therapeutics Inc. | 8 | $5,587 |
| Foundation Medicine, Inc. | 5 | $5,275 |
| Eisai Inc. | 3 | $5,015 |
| Daiichi Sankyo Inc. | 6 | $4,433 |
| AbbVie | 6 | $3,315 |
| Immunogen, Inc. | 3 | $2,271 |
| Bayer | 2 | $1,616 |
| Genentech USA, Inc. | 6 | $1,369 |
| Seagen Inc. | 3 | $174 |
| Clovis Oncology, Inc. | 5 | $131 |
| Tesaro, Inc. | 1 | $61 |
| Pfizer | 1 | $38 |
| Myriad Genetic Laboratories, Inc. | 1 | $36 |
| Merck | 2 | $32 |
| Astellas Pharma US Inc | 1 | $22 |
| Genentech, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYNPARZA$19,302
- ZEJULA$18,750
- JEMPERLI$8,600
- XPOVIO$5,406
- FOUNDATIONACT$5,245
- FOUNDATIONFOCUS$5,245
- FOUNDATIONONE CDX$5,245
- FOUNDATIONONE HEME$5,245
- FOUNDATIONONE$5,245
- LENVIMA$5,015
- Vitrakvi$1,616
- Avastin$1,312
- TECENTRIQ$1,040
- ATACAND$140
- Elahere$117
- Rubraca$104
How this compares
$97,033 in reported general payments places this provider in the 95th percentile of 21 gynecologic oncology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZejulaNiraparib Tosylate | 11 | $195,516 |
| EliquisApixaban | 42 | $23,909 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 24 | $947 |
| Clobetasol Propionate | 12 | $678 |
| Gabapentin | 44 | $631 |
| Prochlorperazine Maleate | 30 | $425 |
| Potassium Chloride | 22 | $292 |
| Ondansetron Hcl | 25 | $204 |
| Mirtazapine | 19 | $190 |
| Duloxetine Hcl | 14 | $188 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 11 | $145 |
| Levothyroxine Sodium | 20 | $93 |
| Prednisone | 24 | $81 |
| Escitalopram Oxalate | 11 | $27 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKZejula | $36,578 | $195,51611 claims |
| PfizerEliquis | $38 | $23,90942 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 21 gynecologic oncology providers in Oklahoma.
Other gynecologic oncology in Oklahoma City
- Camille JacksonOklahoma City$35K
- Tara CastellanoOklahoma City$26K
- Joan WalkerOklahoma City$11K
- Christina WashingtonOklahoma City$9K
- Elizabeth EvansOklahoma City$3K
- Lauren DockeryOklahoma City$3K
- Ana ValenteOklahoma City$2K
- Nicole MinaltOklahoma City$2K
- Jacqueline BohnOklahoma City$1K
- Aleia CrimOklahoma City$862
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.